Current Evidence of the Role of the Myokine Irisin in Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Cancer is a disease associated with extreme human suffering, a huge economic cost to health systems, and is the second leading cause of death worldwide. Regular physical activity is associated with many health benefits, including reduced cancer risk. In the past two decades, exercising/contracting skeletal muscles have been found to secrete a wide range of biologically active proteins, named myokines. Myokines are delivered, via the circulation, to different cells/tissues, bind to their specific receptors and initiate signaling cascades mediating the health benefits of exercise. The present review summarizes the existing evidence of the role of the myokine irisin in cancer. In vitro studies have shown that the treatment of various cancer cells with irisin resulted in the inhibition of cell proliferation, survival, migration/ invasion and induced apoptosis by affecting key proliferative and antiapoptotic signaling pathways. However, the effects of irisin in humans remains unclear. Although the majority of the existing studies have found reduced serum irisin levels in cancer patients, a few studies have shown the opposite. Similarly, the majority of studies have found increased levels of irisin in cancer tissues, with a few studies showing the opposite trend. Clearly, further investigations are required to determine the exact role of irisin in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995 · cited 2×
“Activated Ras leads to the activation of mitogen‐activated protein kinases (MAPK), result‐ ing in tumorigenesis and chemo and radiation resistance [8].”
BackgroundDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α
Jäger, S., Handschin, C., St.-Pierre, J., & Spiegelman, B. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705070104 · Cited by 2,491
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults
Moore, S. C., Lee, I.-M., Weiderpass, E., Campbell, P. T., Sampson, J. N., Kitahara, C. M., Keadle, S. K., Arem, H., Berrington de Gonzalez, A., Hartge, P., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1548 · Cited by 1,487
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973 · cited 4×
“Activated Ras leads to the activation of mitogen-activated protein kinases (MAPK), resulting in tumorigenesis and chemo and radiation resistance [8].”
BackgroundInfluentialThe mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Zhang, Y., Li, R., Meng, Y., Li, S., Donelan, W., Zhao, Y., Qi, L., Zhang, M., Wang, X., Cui, T., et al. (2014) · Diabetes · doi:10.2337/db13-1106 · Cited by 733 · cited 2×
“Two N‐glycosylation sites located at the Asn‐7 and Asn‐52 residues of irisin have been identified and early evidence indicates an important role of glycosylation on the biological activity and function [67].”
BackgroundIrisin Mediates Effects on Bone and Fat via αV Integrin Receptors
Kim, H., Wrann, C. D., Jedrychowski, M., Vidoni, S., Kitase, Y., Nagano, K., Zhou, C., Chou, J., Parkman, V.-J. A., Novick, S. J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.025 · Cited by 638
Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptor α.
Luo, J., Sladek, R., Carrier, J., Bader, J.-A., Richard, D., & Giguère, V. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.7947-7956.2003 · Cited by 370 · cited 1×
“The orphan nuclear receptor estrogen-related receptor alpha (ERRα, also known as NR3B1) is a central metabolic regulator [57,58] and was found to interact with PGC1α to regulate the FNDC5 gene expression [59–61].”
BackgroundShan, T., Liang, X., Bi, P., & Kuang, S. (2013) · The FASEB Journal · doi:10.1096/fj.12-225755 · Cited by 301
Adipo-myokines: two sides of the same coin–mediators of inflammation and mediators of exercise
Raschke, S., & Eckel, J. (2013) · Mediators of Inflammation · doi:10.1155/2013/320724 · Cited by 296
Role of PGC-1α Signaling in Skeletal Muscle Health and Disease
Kang, C., & Li Ji, L. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06738.x · Cited by 291
Progress and Challenges in the Biology of FNDC5 and Irisin
Maak, S., Norheim, F., Drevon, C. A., & Erickson, H. P. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab003 · Cited by 247 · cited 3×
“However, the reliability and validity of the commercially available ELISA assays [48,51,52], utilized in most of the studies to measure irisin in human serum, are questionable and should be resolved.”
BackgroundAydin, S., Kuloglu, T., Aydin, S., Kalayci, M., Yilmaz, M., Cakmak, T., Albayrak, S., Gungor, S., Colakoglu, N., & Ozercan, İ. H. (2014) · Peptides · doi:10.1016/j.peptides.2014.09.014 · Cited by 233
Gamas, L., Matafome, P., & Seiça, R. (2015) · Journal of Diabetes Research · doi:10.1155/2015/359159 · Cited by 114
Bi, J., Zhang, J., Ren, Y., Du, Z., Li, T., Wang, T., Zhang, L., Wang, M., Wu, Z., Lv, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14811 · Cited by 113 · cited 1×
“Similarly, using the immunofluorescence analysis, it was shown in vitro and in vivo that irisin binds to the integrin αVβ5 receptor on gut epithelial cells [46,74].”
MethodActivated PI3K/Akt/COX-2 Pathway Induces Resistance to Radiation in Human Cervical Cancer HeLa Cells
Xia, S., Zhao, Y., Yu, S., & Zhang, M. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0707 · Cited by 78
Significantly greater reduction in breast cancer mortality from post-diagnosis running than walking
Williams, P. T. (2014) · International Journal of Cancer · doi:10.1002/ijc.28740 · Cited by 40
Cited by
Irisin, an exercise-induced bioactive peptide beneficial for health promotion during aging process
Zhang, H., Wu, X., Liang, J., Kirberger, M., & Chen, N. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101680 · Cited by 88
Bettariga, F., Taaffe, D. R., Galvão, D. A., Lopez, P., Bishop, C., Markarian, A. M., Natalucci, V., Kim, J.-S., & Newton, R. U. (2024) · Journal of Sport and Health Science · doi:10.1016/j.jshs.2024.04.005 · Cited by 83
“109 Similarly, researchers recently investigated the effects of AE on irisin expression, observing significant increases after a single bout of exercise.”
BackgroundKazeminasab, F., Sadeghi, E., & Afshari-Safavi, A. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8235809 · Cited by 43
“As a result, the half-life of irisin in humans is less than an hour [48].”
Metadata
- Authors
- Tsiani, E., Tsakiridis, N., Kouvelioti, R., Jaglanian, A., & Klentrou, P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-05-27
- Volume
- 13
- Issue
- 11
- Pages
- 2628
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3165797423
- Cited by
- 51
- References
- 20
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.